Edition:
United States

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

7.30USD
15 Dec 2017
Change (% chg)

$0.25 (+3.55%)
Prev Close
$7.05
Open
$7.10
Day's High
$7.30
Day's Low
$7.10
Volume
3,636
Avg. Vol
4,002
52-wk High
$7.50
52-wk Low
$5.05

Chart for

About

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies,... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $89.93
Shares Outstanding(Mil.): 12.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Chembio receives $8.5 mln commitment from Bio-Manguinhos to purchase components for production of dpp Assays in Brazil during 2018

* CHEMBIO RECEIVES $8.5 MILLION COMMITMENT FROM BIO-MANGUINHOS TO PURCHASE COMPONENTS FOR PRODUCTION OF DPP® ASSAYS IN BRAZIL DURING 2018

Dec 05 2017

BRIEF-Chembio Diagnostics Awarded UNICEF Contract

* CHEMBIO DIAGNOSTICS AWARDED UNICEF CONTRACT TO SUPPLY POINT-OF-CARE DPP® ZIKA ASSAYS AND DPP® MICRO READERS

Nov 28 2017

BRIEF-Chembio Diagnostics posts Q3 loss of $0.05 per share

* Chembio diagnostics reports third quarter 2017 financial results

Nov 08 2017

BRIEF-Chembio Diagnostics CEO has returned to work after a medical leave of absence​

* Chembio Diagnostics Inc - president and CEO ‍John Sperzel has returned to work following a medical leave of absence​ Source text for Eikon: Further company coverage:

Oct 02 2017

BRIEF-Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test

* Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 28 2017

BRIEF-Chembio Diagnostics reports Q2 loss per share of $0.18

* Chembio Diagnostics reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Chembio Diagnostics Inc qtrly ‍net loss $0.18- SEC Filing

* Chembio Diagnostics Inc qtrly ‍net loss of $2.17 million, or $0.18 per diluted share​

Aug 09 2017

BRIEF-Chembio's DPP Zika System including the DPP Micro Reader approved by Brazil's Health Regulatory Agency

* Chembio's DPP® zika system including the DPP® micro reader approved by Brazil's Health Regulatory Agency

Jul 05 2017

BRIEF-Chembio diagnostics announces At-The-Market-Program

* Chembio Diagnostics- announced that it has established an "at--market" program through which it may offer and sell up to $21.2 million of common stock

Jun 27 2017

Competitors

Earnings vs. Estimates